Working... Menu
Trial record 34 of 57 for:    Romidepsin | Phase 2

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03547700
Recruitment Status : Recruiting
First Posted : June 6, 2018
Last Update Posted : July 29, 2019
University of Michigan Rogel Cancer Center
Information provided by (Responsible Party):
Ryan Wilcox, Big Ten Cancer Research Consortium

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : July 2020
  Estimated Study Completion Date : July 2021